866-997-4948(US-Canada Toll Free)

Non-Small Cell Lung Cancer - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Cancer

No. of Pages : 449 Pages


Global Markets Directs, \'Non-Small Cell Lung Cancer Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Non-Small Cell Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer. 

Non-Small Cell Lung Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Non-Small Cell Lung Cancer.
  • A review of the Non-Small Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Non-Small Cell Lung Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Non-Small Cell Lung Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 8
List of Figures 13
Introduction 14
Global Markets Direct Report Coverage 14
Non-Small Cell Lung Cancer Overview 15
Therapeutics Development 16
An Overview of Pipeline Products for Non-Small Cell Lung Cancer 16
Non-Small Cell Lung Cancer Therapeutics under Development by Companies 18
Non-Small Cell Lung Cancer Therapeutics under Investigation by Universities/Institutes 30
Late Stage Products 39
Comparative Analysis 39
Mid Clinical Stage Products 40
Comparative Analysis 40
Early Clinical Stage Products 41
Comparative Analysis 41
Discovery and Pre-Clinical Stage Products 42
Comparative Analysis 42
Non-Small Cell Lung Cancer Therapeutics - Products under Development by Companies 43
Non-Small Cell Lung Cancer Therapeutics - Products under Investigation by Universities/Institutes 65
Companies Involved in Non-Small Cell Lung Cancer Therapeutics Development 76
Bristol-Myers Squibb Company 76
Boehringer Ingelheim GmbH 77
F. Hoffmann-La Roche Ltd. 78
Biogen Idec Inc. 79
Shionogi & Co., Ltd. 80
Amgen Inc. 81
Sanofi-Aventis 82
AstraZeneca PLC 83
Eli Lilly and Company 84
GlaxoSmithKline plc 86
Genentech, Inc. 87
Nektar Therapeutics 88
Inovio Biomedical Corporation 89
MedImmune LLC 90
Isis Pharmaceuticals, Inc. 91
Daiichi Sankyo Company, Ltd 92
Merck & Co., Inc. 93
Infinity Pharmaceuticals, Inc. 94
Takeda Pharmaceutical Company Limited 95
YM BioSciences Inc. 96
Celltrion, Inc. 97
Prolexys Pharmaceuticals, Inc. 98
Millennium Pharmaceuticals, Inc. 99
Novartis AG 100
Astellas Pharma Inc. 101
Biocon Limited 102
Chong Kun Dang Pharmaceutical 103
Eisai Co., Ltd. 104
ImmunoGen, Inc. 105
Laboratoires Pierre Fabre SA 106
Ono Pharmaceutical Co., Ltd. 107
Pfizer Inc. 108
SuperGen, Inc. 109
Taiho Pharmaceutical Co., Ltd. 110
Teva Pharmaceutical Industries Limited 111
Cell Therapeutics, Inc. 112
Exelixis, Inc. 113
Aduro BioTech 114
Cyclacel Pharmaceuticals Inc. 115
Alfacell Corporation 116
Celgene Corporation 117
Bayer AG 118
Geron Corporation 119
Aeolus Pharmaceuticals, Inc. 120
Merck KGaA 121
EntreMed, Inc. 122
Hana Biosciences, Inc. 123
Celldex Therapeutics, Inc. 124
AEterna Zentaris Inc. 125
ImmunoCellular Therapeutics, Ltd. 126
Idera Pharmaceuticals, Inc. 127
Ariad Pharmaceuticals, Inc. 128
Lorus Therapeutics Inc 129
Benitec Ltd. 130
MethylGene Inc 131
Northwest Biotherapeutics, Inc. 132
Novogen Limited 133
Cleveland BioLabs, Inc. 134
Oncothyreon Inc 135
Compugen Ltd. 136
OXiGENE, Inc. 137
Peregrine Pharmaceuticals, Inc. 138
Critical Outcome Technologies Inc. 139
Curis, Inc. 140
Telik, Inc. 141
CytRx Corporation 142
Regeneron Pharmaceuticals, Inc. 143
Oncogenex Pharmaceuticals, Inc. 144
MOLOGEN AG 145
Quest PharmaTech Inc. 146
Threshold Pharmaceuticals, Inc. 147
Synta Pharmaceuticals Corp. 148
Natco Pharma Limited 149
Simcere Pharmaceutical Group 150
Sun Pharma Advanced Research Company 151
Morphotek, Inc. 152
Spectrum Pharmaceuticals, Inc. 153
Chipscreen Biosciences Ltd 154
CIMAB S.A. 155
Bionucleon Srl 156
GANYMED Pharmaceuticals AG 157
Ora Bio Ltd. 158
Philogen S.p.A. 159
NovaRx Corporation 160
Nerviano Medical Sciences S.r.l. 161
Cadila Pharmaceuticals Ltd. 162
Hutchison MediPharma Limited 163
immatics biotechnologies GmbH 164
Vaxon Biotech 165
CureVac GmbH 166
BioNumerik Pharmaceuticals, Inc. 167
Altor BioScience Corporation 168
Alder Biopharmaceuticals Inc. 169
Ascenta Therapeutics, Inc. 170
Cerulean Pharma, Inc. 171
Heat Biologics, Inc. 172
MacroGenics, Inc. 173
OncoMed Pharmaceuticals, Inc. 174
DanDrit Biotech A/S 175
Azaya Therapeutics, Inc. 176
CanBas Co., Ltd. 177
Merrimack Pharmaceuticals, Inc. 178
Neotropix, Inc. 179
Mersana Therapeutics, Inc. 180
Axelar AB 181
Proacta, Inc. 182
Advenchen Laboratories, LLC 183
MolMed S.p.A. 184
Innogene Kalbiotech Pte Ltd. 185
Syndax Pharmaceuticals, Inc. 186
KangLaiTe USA 187
Mirna Therapeutics, Inc. 188
Globeimmune, Inc. 189
Tragara Pharmaceuticals, Inc. 190
Taiwan Liposome Company 191
Cellceutix Corporation 192
PharmaMar, S.A. 193
CG Therapeutics, Inc. 194
Quintessence Biosciences, Inc. 195
Sirnaomics, Inc. 196
Biothera 197
Nereus Pharmaceuticals, Inc. 198
AVEO Pharmaceuticals, Inc. 199
Medisyn Technologies, Inc. 200
Pique Therapeutics 201
Clovis Oncology, Inc. 202
Toko Pharmaceutical Industries Co., Ltd. 203
Cancer Therapeutics CRC Pty Ltd 204
Medical Enzymes AG 205
KAEL-GemVax 206
iCeutica, Inc. 207
Mebiopharm Co., Ltd. 208
Vichem Chemie Research Ltd. 209
Agennix AG 210
Regulon Inc. 211
CellAct Pharma GmbH 212
Oncozyme Pharma Inc. 213
Optimum Therapeutics, LLC 214
Non-Small Cell Lung Cancer - Therapeutics Assessment 215
Assessment by Monotherapy Products 215
Assessment by Combination Products 216
Assessment by Route of Administration 217
Assessment by Molecule Type 220
Drug Profiles 223
eribulin mesylate - Drug Profile 223
motesanib diphosphate - Drug Profile 225
necitumumab - Drug Profile 228
sorafenib tosylate - Drug Profile 230
cetuximab - Drug Profile 234
vandetanib - Drug Profile 240
emepepimut-S - Drug Profile 242
onartuzumab - Drug Profile 245
dacomitinib - Drug Profile 247
crizotinib - Drug Profile 249
dimesna - Drug Profile 252
tegafur + urasil - Drug Profile 330
Docetaxel + S-1 - Drug Profile 331
BV-NSCLC-001 - Drug Profile 332
cisplatin - Drug Profile 333
bevacizumab - Drug Profile 335
erlotinib hydrochloride - Drug Profile 339
erlotinib hydrochloride - Drug Profile 342
celecoxib + [carboplatin] + [gemcitabine hydrochloride] + [pemetrexed disodium] - Drug Profile 345
cediranib maleate + [carboplatin] + [paclitaxel] - Drug Profile 346
cetuximab + [carboplatin] + [paclitaxel] - Drug Profile 348
Docetaxel + Carboplatin - Drug Profile 350
(tegafur + gimeracil + oteracil potassium) - Drug Profile 351
talactoferrin alfa + [carboplatin] + [paclitaxel] - Drug Profile 354
Recombinant Human Endostatin + [cisplatin] + [vinorelbine tartrate] - Drug Profile 356
cetuximab + [bevacizumab] + [carboplatin] + [paclitaxel] - Drug Profile 358
bevacizumab biosimilar - Drug Profile 360
Non-Small Cell Lung Cancer Therapeutics - Drug Profile Updates 361
Non-Small Cell Lung Cancer Therapeutics - Discontinued Products 402
Non-Small Cell Lung Cancer Therapeutics - Dormant Products 409
Non-Small Cell Lung Cancer - Product Development Milestones 436
Featured News & Press Releases 436

Appendix 443
Methodology 443
Coverage 443
Secondary Research 443
Primary Research 443
Expert Panel Validation 443
Contact Us 444
Disclaimer 444

List of Table


Number of Products Under Development for Non-Small Cell Lung Cancer, H1 2013 21
Products under Development for Non-Small Cell Lung Cancer - Comparative Analysis, H1 2013 22
Number of Products under Development by Companies, H1 2013 24
Number of Products under Development by Companies, H1 2013 (Contd..1) 25
Number of Products under Development by Companies, H1 2013 (Contd..2) 26
Number of Products under Development by Companies, H1 2013 (Contd..3) 27
Number of Products under Development by Companies, H1 2013 (Contd..4) 28
Number of Products under Development by Companies, H1 2013 (Contd..5) 29
Number of Products under Development by Companies, H1 2013 (Contd..6) 30
Number of Products under Development by Companies, H1 2013 (Contd..7) 31
Number of Products under Development by Companies, H1 2013 (Contd..8) 32
Number of Products under Development by Companies, H1 2013 (Contd..9) 33
Number of Products under Development by Companies, H1 2013 (Contd..10) 34
Number of Products under Investigation by Universities/Institutes, H1 2013 36
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 37
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 38
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..3) 39
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..4) 40
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..5) 41
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..6) 42
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..7) 43
Comparative Analysis by Late Stage Development, H1 2013 44
Comparative Analysis by Mid Clinical Stage Development, H1 2013 45
Comparative Analysis by Early Clinical Stage Development, H1 2013 46
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 47
Products under Development by Companies, H1 2013 48
Products under Development by Companies, H1 2013 (Contd..1) 49
Products under Development by Companies, H1 2013 (Contd..2) 50
Products under Development by Companies, H1 2013 (Contd..3) 51
Products under Development by Companies, H1 2013 (Contd..4) 52
Products under Development by Companies, H1 2013 (Contd..5) 53
Products under Development by Companies, H1 2013 (Contd..6) 54
Products under Development by Companies, H1 2013 (Contd..7) 55
Products under Development by Companies, H1 2013 (Contd..8) 56
Products under Development by Companies, H1 2013 (Contd..9) 57
Products under Development by Companies, H1 2013 (Contd..10) 58
Products under Development by Companies, H1 2013 (Contd..11) 59
Products under Development by Companies, H1 2013 (Contd..12) 60
Products under Development by Companies, H1 2013 (Contd..13) 61
Products under Development by Companies, H1 2013 (Contd..14) 62
Products under Development by Companies, H1 2013 (Contd..15) 63
Products under Development by Companies, H1 2013 (Contd..16) 64
Products under Development by Companies, H1 2013 (Contd..17) 65
Products under Development by Companies, H1 2013 (Contd..18) 66
Products under Development by Companies, H1 2013 (Contd..19) 67
Products under Development by Companies, H1 2013 (Contd..20) 68
Products under Development by Companies, H1 2013 (Contd..21) 69
Products under Investigation by Universities/Institutes, H1 2013 70
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 71
Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 72
Products under Investigation by Universities/Institutes, H1 2013 (Contd..3) 73
Products under Investigation by Universities/Institutes, H1 2013 (Contd..4) 74
Products under Investigation by Universities/Institutes, H1 2013 (Contd..5) 75
Products under Investigation by Universities/Institutes, H1 2013 (Contd..6) 76
Products under Investigation by Universities/Institutes, H1 2013 (Contd..7) 77
Products under Investigation by Universities/Institutes, H1 2013 (Contd..8) 78
Products under Investigation by Universities/Institutes, H1 2013 (Contd..9) 79
Products under Investigation by Universities/Institutes, H1 2013 (Contd..10) 80
Bristol-Myers Squibb Company, H1 2013 81
Boehringer Ingelheim GmbH, H1 2013 82
F. Hoffmann-La Roche Ltd., H1 2013 83
Biogen Idec Inc., H1 2013 84
Shionogi & Co., Ltd., H1 2013 85
Amgen Inc., H1 2013 86
Sanofi-Aventis, H1 2013 87
AstraZeneca PLC, H1 2013 88
Eli Lilly and Company, H1 2013 89
GlaxoSmithKline plc, H1 2013 91
Genentech, Inc., H1 2013 92
Nektar Therapeutics, H1 2013 93
Inovio Biomedical Corporation, H1 2013 94
MedImmune LLC, H1 2013 95
Isis Pharmaceuticals, Inc., H1 2013 96
Daiichi Sankyo Company, Ltd, H1 2013 97
Merck & Co., Inc., H1 2013 98
Infinity Pharmaceuticals, Inc., H1 2013 99
Takeda Pharmaceutical Company Limited, H1 2013 100
YM BioSciences Inc., H1 2013 101
Celltrion, Inc., H1 2013 102
Prolexys Pharmaceuticals, Inc., H1 2013 103
Millennium Pharmaceuticals, Inc., H1 2013 104
Novartis AG, H1 2013 105
Astellas Pharma Inc., H1 2013 106
Biocon Limited, H1 2013 107
Chong Kun Dang Pharmaceutical, H1 2013 108
Eisai Co., Ltd., H1 2013 109
ImmunoGen, Inc., H1 2013 110
Laboratoires Pierre Fabre SA, H1 2013 111
Ono Pharmaceutical Co., Ltd., H1 2013 112
Pfizer Inc., H1 2013 113
SuperGen, Inc., H1 2013 114
Taiho Pharmaceutical Co., Ltd., H1 2013 115
Teva Pharmaceutical Industries Limited, H1 2013 116
Cell Therapeutics, Inc., H1 2013 117
Exelixis, Inc., H1 2013 118
Aduro BioTech, H1 2013 119
Cyclacel Pharmaceuticals Inc., H1 2013 120
Alfacell Corporation, H1 2013 121
Celgene Corporation, H1 2013 122
Bayer AG, H1 2013 123
Geron Corporation, H1 2013 124
Aeolus Pharmaceuticals, Inc., H1 2013 125
Merck KGaA, H1 2013 126
EntreMed, Inc., H1 2013 127
Hana Biosciences, Inc., H1 2013 128
Celldex Therapeutics, Inc., H1 2013 129
AEterna Zentaris Inc., H1 2013 130
ImmunoCellular Therapeutics, Ltd., H1 2013 131
Idera Pharmaceuticals, Inc., H1 2013 132
Ariad Pharmaceuticals, Inc., H1 2013 133
Lorus Therapeutics Inc, H1 2013 134
Benitec Ltd., H1 2013 135
MethylGene Inc, H1 2013 136
Northwest Biotherapeutics, Inc., H1 2013 137
Novogen Limited, H1 2013 138
Cleveland BioLabs, Inc., H1 2013 139
Oncothyreon Inc, H1 2013 140
Compugen Ltd., H1 2013 141
OXiGENE, Inc., H1 2013 142
Peregrine Pharmaceuticals, Inc., H1 2013 143
Critical Outcome Technologies Inc., H1 2013 144
Curis, Inc., H1 2013 145
Telik, Inc., H1 2013 146
CytRx Corporation, H1 2013 147
Regeneron Pharmaceuticals, Inc., H1 2013 148
Oncogenex Pharmaceuticals, Inc., H1 2013 149
MOLOGEN AG, H1 2013 150
Quest PharmaTech Inc., H1 2013 151
Threshold Pharmaceuticals, Inc., H1 2013 152
Synta Pharmaceuticals Corp., H1 2013 153

List of Chart


Number of Products under Development for Non-Small Cell Lung Cancer, H1 2013 21
Products under Development for Non-Small Cell Lung Cancer - Comparative Analysis, H1 2013 22
Products under Development by Companies, H1 2013 23
Products under Investigation by Universities/Institutes, H1 2013 35
Late Stage Products, H1 2013 44
Mid Clinical Stage Products, H1 2013 45
Early Clinical Stage Products, H1 2013 46
Discovery and Pre-Clinical Stage Products, H1 2013 47
Assessment by Monotherapy Products, H1 2013 220
Assessment by Combination Products, H1 2013 221
Assessment by Route of Administration, H1 2013 222
Assessment by Stage and Route of Administration, H1 2013 223
Assessment by Molecule Type, H1 2013 225
Assessment by Stage and Molecule Type, H1 2013 226

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *